← Back to Clinical Trials
Recruiting NCT04340986

NCT04340986 Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04340986
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Cholangiocarcinoma
Study Type OBSERVATIONAL
Enrollment 1,250 participants
Start Date 2020-09-02
Primary Completion 2030-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,250 participants in total. It began in 2020-09-02 with a primary completion date of 2030-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Eligibility Criteria

Inclusion Criteria: Inclusion Criteria : * Age ≥ 18 years olds * Medical care in Nephrology department since 2015 Cholangiocarcinoma: \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease Hepatocellular carcinoma: * Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI * Hepatocellular histologically documented Exclusion Criteria: \- Lack of patient non-opposition

Contact & Investigator

Central Contact

Marie LEQUOY, MD

✉ marie.lequoy@aphp.fr

📞 +330149283154

Principal Investigator

Marie LEQUOY, MD

PRINCIPAL INVESTIGATOR

AssistancePublique-Hôpitaux de Paris

Frequently Asked Questions

Who can join the NCT04340986 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04340986 currently recruiting?

Yes, NCT04340986 is actively recruiting participants. Contact the research team at marie.lequoy@aphp.fr for enrollment information.

Where is the NCT04340986 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT04340986 clinical trial?

NCT04340986 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Marie LEQUOY, MD at AssistancePublique-Hôpitaux de Paris. The trial plans to enroll 1,250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology